Vanda Pharmaceuticals (NASDAQ:VNDA) Issues Quarterly Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.31, FiscalAI reports. Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. The business had revenue of $1.61 million for the quarter, compared to analyst estimates of $69.20 million.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Third-quarter revenue rose 24% year over year to $69.8 million, driven by continued FANAPT growth, favorable HETLIOZ shipment timing, and early NEREUS sales. FANAPT prescriptions increased 25% year over year, while NEREUS prescriptions and unique prescribers each more than doubled sequentially.
• Vanda expects to launch BYSANTI in the fourth quarter of 2026, with commercial supplies nearly ready, and is preparing for a potential Quimilza launch in the first half of 2027 if the FDA approves its GPP application by the December 12 PDUFA date.
• Positive Phase III results could expand NEREUS into prevention of GLP-1-associated vomiting and HETLIOZ into delayed sleep-wake phase disorder. Management plans to discuss both programs with the FDA and pursue supplemental applications.
• Operating expenses declined 18% sequentially to $93.3 million as major development and launch-preparation activities concluded, and management expects further reductions in coming quarters.
• Vanda ended September with $140.5 million in cash, down $123.4 million from year-end 2025, and expects 2026 cash burn to exceed 2025 levels. HETLIOZ revenue remains vulnerable to generic competition and specialty-pharmacy inventory normalization, while NEREUS 2026 revenue is expected to remain below $10 million.

Vanda Pharmaceuticals Trading Up 0.3%

Shares of Vanda Pharmaceuticals stock traded up $0.01 during trading on Wednesday, reaching $4.00. 1,996,913 shares of the company were exchanged, compared to its average volume of 1,491,518. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $9.94. The business has a 50-day moving average price of $4.88 and a 200-day moving average price of $6.27. The firm has a market capitalization of $241.85 million, a price-to-earnings ratio of -0.86 and a beta of 0.69.

Analysts Set New Price Targets

Several equities research analysts have weighed in on VNDA shares. HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Oppenheimer assumed coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price target on the stock. Zacks Research cut shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Finally, B. Riley Financial reissued a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.08.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.